NASDAQ: HCAT - Health Catalyst, Inc.

Yield per half year: +14.58%
Sector: Healthcare

Company Analysis Health Catalyst, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (8.05 $) is less than fair price (8.99 $)

Disadvantages

  • Dividends (0%) are below the sector average (0.5442%).
  • The stock's return over the last year (-27.32%) is lower than the sector average (-20.76%).
  • Current debt level 32.97% has increased over 5 years from 1.16%.
  • The company's current efficiency (ROE=-32.2%) is lower than the sector average (ROE=9.61%)

Similar companies

Alexion

ABIOMED

Amgen

Gilead Sciences

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Health Catalyst, Inc. Healthcare Index
7 days -0.2% -17.8% 0%
90 days -17.1% -25.3% 8.9%
1 year -27.3% -20.8% 30.8%

HCAT vs Sector: Health Catalyst, Inc. has significantly underperformed the "Healthcare" sector by -6.56% over the past year.

HCAT vs Market: Health Catalyst, Inc. has significantly underperformed the market by -58.09% over the past year.

Stable price: HCAT is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: HCAT with weekly volatility of -0.5255% over the past year.

3. Summary of the report

3.1. General

P/E: 17.01
P/S: 1.81

3.2. Revenue

EPS -2.09
ROE -32.2%
ROA -16.83%
ROIC -22.43%
Ebitda margin -13.7%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (8.05 $) is lower than the fair price (8.99 $).

Price not significantly lower than the fair price: The current price (8.05 $) is slightly lower than the fair price by 11.7%.

4.2. P/E

P/E vs Sector: The company's P/E (17.01) is lower than that of the sector as a whole (48.77).

P/E vs Market: The company's P/E (17.01) is lower than that of the market as a whole (48.79).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (1.46) is lower than that of the sector as a whole (4.82).

P/BV vs Market: The company's P/BV (1.46) is lower than that of the market as a whole (3.36).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (1.81) is lower than that of the sector as a whole (33.76).

P/S vs Market: The company's P/S indicator (1.81) is lower than that of the market as a whole (10.23).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-16.75) is higher than that of the sector as a whole (-22.15).

EV/Ebitda vs Market: The company's EV/Ebitda (-16.75) is lower than that of the market as a whole (28.28).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 19.38% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (19.38%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).

5.4. ROE

ROE vs Sector: The company's ROE (-32.2%) is lower than that of the sector as a whole (9.61%).

ROE vs Market: The company's ROE (-32.2%) is lower than that of the market as a whole (10.82%).

5.5. ROA

ROA vs Sector: The company's ROA (-16.83%) is lower than that of the sector as a whole (0.3443%).

ROA vs Market: The company's ROA (-16.83%) is lower than that of the market as a whole (6.51%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-22.43%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (-22.43%) is lower than that of the market as a whole (10.79%).

6. Finance

6.1. Assets and debt

Debt level: (32.97%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 1.16% to 32.97%.

Excess of debt: The debt is not covered by net income, percentage -195.85%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5442%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Selling More insider purchases by 100% over the last 3 months.

8.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
05.11.2024 LeSueur Daniel
Chief Operating Officer
Sale 7.7 40 109 5 209
03.10.2024 LeSueur Daniel
Chief Operating Officer
Sale 7.68 40 005 5 209
03.07.2024 LeSueur Daniel
Chief Operating Officer
Sale 6.15 32 029 5 208
06.12.2023 Alger Jason
Chief Accounting Officer
Sale 7.55 16 436 2 177
05.06.2023 Hunt Bryan Truman
Chief Financial Officer
Sale 12 7 800 650

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Health Catalyst, Inc.

9.3. Comments